Stifel raised the firm’s price target on Allogene Therapeutics to $4.60 from $4.40 and keeps a Hold rating on the shares after a Q1 update that the firm says “largely reiterated near-term objectives.” The firm raised its view of the odds of success for ALPHA3 to 45%, but could see this move higher or lower based on enrollment enthusiasm “so long as there’s appetite to enroll,” the analyst tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALLO:
- Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
- Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
- ALLO Upcoming Earnings Report: What to Expect?
- Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma
- Allogene awarded $15M grant from CIRM to support ALLO-316 development